NCT01003769 2020-06-16
Lenalidomide and AT-101 in Treating Patients With Relapsed B-Cell Chronic Lymphocytic Leukemia
Mayo Clinic
Phase 1/2 Terminated
Clinical Trials
5 trialsNCT00561197 2013-01-04
An Open-label, Single-center, Phase 1/ 2 Study of Chemoradiotherapy and AT-101 in Patients With Locally Advanced Esophageal or Gastroesophageal Junction Cancer
Ascenta Therapeutics
Phase 1/2 Terminated
NCT00286793 2011-06-29
Safety and Efficacy Study of AT-101 in Combination With Docetaxel and Prednisone in Men With HRPC
Ascenta Therapeutics
Phase 1/2 Completed
NCT00286806 2010-08-24
A Study of Single-Agent AT-101 in Men With Hormone Refractory Prostate Cancer
Ascenta Therapeutics
Phase 1/2 Completed
NCT00397293 2010-08-24
Study of AT-101 in Combination With Topotecan in Relapsed/Refractory Small Cell Lung Cancer
Ascenta Therapeutics
Phase 1/2 Completed